Note 17. Stock-Based Compensation Plans

Stock option plans

The Company has two stock option plans, the Omnibus Long-Term Incentive Plan and the Sharesave Plan 2008 under which it can currently grant awards. The stock options have vesting periods ranging from 24 months to 5 years and in all cases stock options granted expire within 10 years of the date of grant. All grants are at the sole discretion of the Compensation Committee of the Board of Directors. Grants may be priced at market value or at a premium or discount. The aggregate number of shares of common stock reserved for issuance which can be granted under the plans is 2,550,000.

The fair value of stock options is measured on the grant date using either the Black-Scholes model, or in cases where performance criteria are dependent upon external factors such as the Company’s stock price, using a Monte Carlo model. The following weighted average assumptions were used to determine the grant-date fair value of options:


	2018			2017			2016
Dividend yield		1.11	%		0.96	%		1.38	%
Expected life		5 years			5 years			5 years
Volatility		25.6	%		25.3	%		25.1	%
Risk free interest rate		2.74	%		1.50	%		0.91	%

The following table summarizes the transactions of the Company’s stock option plans for the year ended December 31, 2018:


	Number of Options			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value
Outstanding at December 31, 2017		357,666		$	13.74	$	35.69
Granted – at discount		287,966		$	45.21	$	34.98
– at market value		18,850		$	68.20	$	16.23
Exercised		(103,562	)	$	11.00	$	29.78
Forfeited		(15,671	)	$	24.35	$	25.38

Outstanding at December 31, 2018		545,249		$	32.46	$	36.06

At December 31, 2018, there were 41,014 stock options that were exercisable, 1,600 had performance conditions attached.

The Company’s policy is to issue shares from treasury stock to holders of stock options who exercise those options, but if sufficient treasury stock is not available, the Company will issue previously unissued shares of stock to holders of stock options who exercise options.

The stock option compensation cost for 2018, 2017 and 2016 was $4.9 million, $4.2 million and $3.3 million, respectively. The total intrinsic value of options exercised in 2018, 2017 and 2016 was $3.2 million, $2.9 million and $2.8 million, respectively.

The total compensation cost related to non-vested stock options not yet recognized at December 31, 2018 was $10.7 million and this cost is expected to be recognized over the weighted-average period of 2.19 years.

In 2018, the Company recorded a current tax benefit of $1.2 million in respect of stock option compensation (2017 – $3.0 million). This amount is inclusive of excess tax benefits.

No stock options awards were modified in 2018, 2017 or 2016.

Stock equivalent units

The Company awards Stock Equivalent Units (“SEUs”) from time to time as a long-term performance incentive. SEUs are cash settled equity instruments conditional on certain performance criteria and linked to the Innospec Inc. share price. SEUs have vesting periods ranging from 11 months to 4 years and in all cases SEUs granted expire within 10 years of the date of grant. Grants may be priced at market value or at a premium or discount. There is no limit to the number of SEUs that can be granted. As at December 31, 2018 the liability for SEUs of $15.1 million is located in accrued liabilities in the consolidated balance sheets until they are cash settled.

The fair value of SEUs is measured at the balance sheet date using either the Black-Scholes model, or in cases where performance criteria are dependent upon external factors such as the Company’s stock price, using a Monte Carlo model. The following assumptions were used to determine the fair value of SEUs at the balance sheet dates:


	2018			2017			2016
Dividend yield		1.44	%		1.09	%		0.98	%
Volatility		27.2	%		25.4	%		25.2	%
Risk free interest rate		2.46	%		1.98	%		1.47	%

The following table summarizes the transactions of the Company’s SEUs for the year ended December 31, 2018:


	Number of SEUs			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value
Outstanding at December 31, 2017		400,342		$	3.10	$	46.65
Granted – at discount		115,229		$	2.36	$	57.16
– at market value		5,658		$	68.20	$	16.23
Exercised		(78,239	)	$	5.40	$	30.44
Forfeited		(24,054	)	$	0.96	$	41.58

Outstanding at December 31, 2018		418,936		$	3.47	$	52.45

At December 31, 2018, there were 34,710 SEUs that were exercisable, 32,005 had performance conditions attached.

The charges for SEUs are spread over the life of the award subject to a revaluation to fair value each quarter. The revaluation may result in a charge or a credit to the income statement in the quarter dependent upon our share price and other performance criteria.

The SEU compensation cost for 2018, 2017 and 2016 was $5.7 million, $6.6 million and $4.7 million, respectively. The total intrinsic value of SEUs exercised in 2018, 2017 and 2016 was $2.7 million, $1.7 million and $1.8 million, respectively.

The weighted-average remaining vesting period of non-vested SEUs is 1.73 years.